Cytotoxicity test and cytogenetic analysis of effects of aminoguanidine in vitro

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 25, Issue 1, 2003, Pages 11-15

  Vojtaššák, Ján ^a   Carsky J ^b   Bohmer D ^a   Braxatorisova T ^a   Geislerova V ^a   Durikova M ^a   Pagacova E ^a   Repiska V ^a   Danisovic L ^a   Blasko M ^a  

^a Bratislava   (Slovakia)

^b Faculty of Natural Sciences   (Slovakia)

Author keywords

AGE; Aminoguanidine; Cytotoxicity test; Glycoxidation; Growth curves; Karyological analysis; Micronucleus test

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE;

ARTICLE; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOGENETICS; CYTOTOXICITY; DIPLOIDY; FETUS; GLYCATION; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; KARYOTYPE; MALE; MICRONUCLEUS; SYNTHESIS; TOXICITY TESTING;

CELL LINE; CYTOGENETIC ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANIDINES; HUMANS; MALE; MICRONUCLEUS TESTS;

EID: 17444437548     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2003.25.1.772542     Document Type: Article

References (16)

1. Brownlee, M. Negative consequences of glycation (review). Metabolism 2000, 49: 9-13.
2. Bucala, R., Cerami, A., Vlassara, H. Advanced glycosylation end-products in diabetic complications: Biochemical basis and prospects of therapeutic intervention. Diabetes Rev 1995, 3: 258-68.
3. Brownlee, M., Vlassara, H., Kooney, A., Ulrich, P., Cerami, A. Aminoguanidine prevents diabetes-induced arterial wall protein cros-linking. Science 1986, 232: 1629-32.
4. Price, D.L., Rhett, P.M., Thorpe, S.R., Baynes, J.W. Chelating activity of advanced glycation end-product inhibiors. J Biol Chem 2001, 276 (52): 48967-72.
5. Jakuš, V., Hrnčiarová, M., Čársky, J., Krahulec, B., Rietbrock, N. Inhibition of nonenzyatic protein glycation and lipid peroxidation by drug with antioxidant activity. Life Sci 1999, 65: 1993-4.
6. Taguchi, T., Sugiura, M., Hamada, Y., Miwa, I. Inhibition of advanced protein glycation by a Schiff base between aminoguanidine and pyridoxal. Eur J Pharmacol 1999, 378: 283-9.
7. Popovic, M., Klobušická, K., Phan Thu, A., Blaško, M. Comparative in vitro studies of human fibroblastic cells derived from fibrosarcoma, fibroma and various organs of fetus. Neoplasma 1979, 26: 185-93.
8. Chen, T.R. In situ detection of mycoplasm contamination in cultures by fluorescent Hoechsts 33258 stain. Exp Cell Res 1977, 104: 255-62.
9. Blaško, M., Tomšík, F., Bielek, J. Freezing aggregates for biological containers (BK35 and BK10). In: Bulletin IIF V of I. Conf: Biology of low temperatures. Opocno, Czechoslovakia. 1975: 39.
10. Countryman, P. I., Heddle, J.A: The production of micronuclei from chromosome aberrations in irradiated cultures of human lymphocytes. Mutation Res 1976, 41: 324.
11. Skamauskas, J.T., McKay, A.G., Hunt, J.V. Aminoguanidine and its pro-oxidant effect on an experimental model of protein glycation. Free Rad Biol Med 1996, 21: 801-12.
12. Sugyiama, T., Miyamoto, K., Katagiri, S. Fetal toxicity of aminoguanidine in mice and rats. J Toxicol Sc 1986, 11: 189-95.
13. Chappey, O., Dosquet, C., Wautier, M.P., Wautier, J.L. Advanced glycation end-products, oxidant stress and vascular lesions. Eur J Clin Invest 1997, 27: 97-108.
14. Amphlett, G.E., Delow, G.F. Statistical analysis of the micronucleus test. Mutat Res 1984, 128: 161-6.
15. Evans, H.J., Neary, G.J., William, F.S. The relative biological efficiency of single doses of first neutrons and gamma rays on Vicia faba roots and the effect of oxygen. II. Chromosome damage: The production of micromolecules. Int J Rad Biol 1959, 1: 216-20.
16. Hoegstedt, B., Karlsson, A. The size of micronuclei in human lymphocytes varies according to inducing agent used. Mutat Res 1985, 156: 229-32.